Author:
Walsh Ryan R.,Krismer Florian,Galpern Wendy R.,Wenning Gregor K.,Low Phillip A.,Halliday Glenda,Koroshetz Walter J.,Holton Janice,Quinn Niall P.,Rascol Olivier,Shaw Leslie M.,Eidelberg David,Bower Pam,Cummings Jeffrey L.,Abler Victor,Biedenharn Judy,Bitan Gal,Brooks David J.,Brundin Patrik,Fernandez Hubert,Fortier Philip,Freeman Roy,Gasser Thomas,Hewitt Art,Höglinger Günter U.,Huentelman Matt J.,Jensen Poul H.,Jeromin Andreas,Kang Un Jung,Kaufmann Horacio,Kellerman Lawrence,Khurana Vikram,Klockgether Thomas,Kim Woojin Scott,Langer Carol,LeWitt Peter,Masliah Eliezer,Meissner Wassilios,Melki Ronald,Ostrowitzki Susanne,Piantadosi Steven,Poewe Werner,Robertson David,Roemer Cyndi,Schenk Dale,Schlossmacher Michael,Schmahmann Jeremy D.,Seppi Klaus,Shih Lily,Siderowf Andrew,Stebbins Glenn T.,Stefanova Nadia,Tsuji Shoji,Sutton Sharon,Zhang Jing
Abstract
Multiple system atrophy (MSA) is a rare neurodegenerative disorder with substantial knowledge gaps despite recent gains in basic and clinical research. In order to make further advances, concerted international collaboration is vital. In 2014, an international meeting involving leaders in the field and MSA advocacy groups was convened in Las Vegas, Nevada, to identify critical research areas where consensus and progress was needed to improve understanding, diagnosis, and treatment of the disease. Eight topic areas were defined: pathogenesis, preclinical modeling, target identification, endophenotyping, clinical measures, imaging biomarkers, nonimaging biomarkers, treatments/trial designs, and patient advocacy. For each topic area, an expert served as a working group chair and each working group developed priority-ranked research recommendations with associated timelines and pathways to reach the intended goals. In this report, each groups' recommendations are provided.
Publisher
Ovid Technologies (Wolters Kluwer Health)